Table 2.

Summary of studies comparing Cal/BD aerosol foam with Cal/BD gel or ointment

References	Study identifier	Design	Duration (weeks)	N	Comparator(s)	Outcomes
Queille-Roussel [49]	NCT01347255	Phase IIa, exploratory, single-center, intra-individual comparison	4	24	Cal/BD foam vs. Cal/BD ointment vs. BD foam vs. foam vehicle (all n = 24)	TCS decrease: −6.00 vs. −5.25 (Cal/BD ointment; P = 0.038), vs. −4.96 (BD foam; P = 0.005)
Koo et al. [51]	NCT01536886	Phase II, randomized, multicenter	4	376	Cal/BD foam (n = 141) vs. Cal/BD ointment (n = 135) vs. foam (n = 49) and ointment (n = 51) vehicle	Treatment success rates: 54.6% vs. 43.0% (Cal/BD ointment; P = 0.025); mPASI mean difference: −0.6 vs. Cal/BD ointment (P = 0.005)
Paul et al. [52]	NCT02132936	Phase III, randomized, parallel-group (PSO-ABLE)	12	463	Cal/BD foam (n = 185) vs. Cal/BD gel (n = 188) vs. foam (n = 47) and gel (n = 43) vehicle	Treatment success rates: 38% vs. 22% (Cal/BD gel; P < 0.001); mPASI mean difference: −0.6 vs. Cal/BD gel (P = 0.028)
Paul et al. [53]	NCT02132936	Phase III, randomized, parallel-group (PSO-ABLE secondary, HRQoL analysis)	12	463	Cal/BD foam (n = 185) vs. Cal/BD gel (n = 188)	DLQI scores of 0/1: 61% vs. 44% (Cal/BD gel; P = 0.003); EQ-5D utility index: 0.09 vs. 0.03 (Cal/BD gel; P < 0.001)

All studies were investigator-blinded

BD bethamethasone dipropionate 0.5 mg/g, Cal calcipotriol 50 μg/g, DLQI Dermatology Life Quality Index, EQ-5D EuroQoL-5D-5L-PSO, HRQoL health-related quality of life, mPASI modified Psoriasis Area and Severity Index (excluding the head, which was not measured), TCS total clinical score (sum of erythema, scaling and plaque thickness)